Age-Related Macular Degeneration
GALLEGO-GR40973 (Sponsor: Roche/Genentech)
2019-present
NCT Number: NCT03972709
A Phase II, Multi-Center, Randomized, Single-Masked, Sham Injection Controlled Study of the Safety, Tolerability, and Evidence of Activity of Intravitreal Injection of R7171009 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
For more information, click here.
Age-Related Macular Degeneration
SPIAM-202 (Sponsor: Stealth)
2019-present
NCT Number: NCT03891875
A Phase II, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy and Pharmakinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy
For more information, click here.
Age-Related Macular Degeneration
APL2-304 (Sponsor: Apellis)
2018-present
NCT Number: NCT03525613
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
For more information, click here.
Age-Related Macular Degeneration
Tenaya GR40306 (Sponsor: Roche/Genentech)
2019-present
NCT Number: NCT03823287
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate R06867461 in Patients with Neovascular Age-Related Macular Degeneration
For more information, click here.
Diabetic Retinopathy
Robin (Sponsor: Boehringer Ingelheim)
2017-present
NCT Number: NCT03238963
A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with nonproliferative diabetic retinopathy without center-involved diabetic macular edema
For more information, click here.
Age-Related Macular Degeneration
Panda KHB-1802 (Sponsor: Chengdu)
2018-present
NCT Number: NCT03630952
A Phase III, Multi-Center, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration
For more information, click here.
Diabetic Macular Edema
Yosemite- GR40349 (Sponsor: Roche/Genentech)
2018-present
NCT Number: NCT03622580
A Phase III, Multi-Center, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema
For more information, click here.
Age-Related Macular Degeneration
Archway Ranibizumab GR40548 (Sponsor: Roche/Genentech)
2018-present
NCT Number: NCT03677934
A Phase III, Multi-Center, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with NeoVascular Age-Related Macular Degeneration
For more information, click here.
Age-Related Macular Degeneration
Candela (Sponsor: Roche/Genentech)
2019-present
NCT Number: NCT04126317
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
For more information, click here.
Kodiak Sciences Inc., KS301P107 DAYLIGHT
A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Kodiak Sciences Inc., KS301P103 BEACON
A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Visual Impairment Due to Treatment-naïve Macular Edema
Secondary to Retinal Vein Occlusion (RVO)
Kodiak Sciences Inc., KS301P104 GLEAM
A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Visual Impairment Secondary to Treatment-naïve Diabetic
Macular Edema (DME)
REGENXBIO Inc., RGX-314-2202 ALTITUDE
A Phase 2, Randomized, Dose-escalation, Observation-controlled
Study to Evaluate the Efficacy, Safety, and Tolerability of
RGX-314 Gene Therapy Delivered via a Single Suprachoroidal
Space (SCS) Injection in Participants with Diabetic Retinopathy
(DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)
Opthea OPT-302-1005 COAST
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate
the Efficacy and Safety of Intravitreal OPT-302 in Combination with
Aflibercept, Compared with Aflibercept Alone, in Participants with
Neovascular Age-related Macular Degeneration (nAMD)
Opthea OPT-302-1005 SHORE
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the
Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab,
Compared with Ranibizumab Alone, in Participants with Neovascular Age-related
Macular Degeneration (nAMD)
F. Hoffmann-La Roche Ltd, GR41984 BALATON
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled
Study To Evaluate Theefficacy And Safety Of Faricimab Inpatients With Macular Edema Secondary
To Branch Retinal Vein Occlusion